Hille Vax, Inc. HLVX
Institutional shares held
4.16 Million
0
calls
0
puts
Total value of holdings
$8.7M
$0
calls
$0
puts
Market Cap
$69.9M
33,427,200
Shares Out.
Institutional ownership
12.45%
# of Institutions
7
We take great care to ensure that the data presented and summarized in this overview for HilleVax, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HLVX
View all-
Black Rock Inc. New York, NY2.09MShares$4.37 Million0.0% of portfolio
-
Abingworth LLP London, X01.84MShares$3.84 Million10.2% of portfolio
-
Xtx Topco LTD London, X0179KShares$374,4940.02% of portfolio
-
Tekla Capital Management LLC27KShares$56,4290.02% of portfolio
-
Credit Suisse Ag Zurich, V815.7KShares$32,7870.0% of portfolio
-
ETF Managers Group, LLC Summit, NJ10.9KShares$22,6910.01% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$0100.0% of portfolio
Latest Institutional Activity in HLVX
Top Purchases
Top Sells
About HLVX
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Insider Transactions at HLVX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 17
2025
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
6,724,000
-100.0%
|
$6,724,000
$1.95 P/Share
|
|
Sep 17
2025
|
Frazier Life Sciences X, L.P. |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
8,552,536
-100.0%
|
$8,552,536
$1.95 P/Share
|
|
Sep 17
2025
|
Shane Maltbie Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
83,738
-100.0%
|
-
|
|
Sep 17
2025
|
Jaime Sepulveda |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
59,224
-100.0%
|
-
|
|
Sep 17
2025
|
Julie L. Gerberding |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
59,224
-100.0%
|
-
|
|
Sep 17
2025
|
Aditya Kohli |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
698,171
-100.0%
|
-
|
|
Sep 17
2025
|
Gary Dubin |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,199
-100.0%
|
-
|
|
Sep 17
2025
|
Shelley Chu |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,199
-100.0%
|
-
|
|
Sep 17
2025
|
Jeryl L Hilleman |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
59,224
-100.0%
|
-
|
|
Sep 17
2025
|
Nanette Cocero |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,199
-100.0%
|
-
|
|
Sep 17
2025
|
Robert Hershberg President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,101,498
-100.0%
|
-
|
|
Jun 23
2025
|
Patrick J Heron |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+50.0%
|
-
|
|
Jun 23
2025
|
Aditya Kohli |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+2.4%
|
-
|
|
Jun 23
2025
|
Shelley Chu |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+50.0%
|
-
|
|
Jun 23
2025
|
Jaime Sepulveda |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+22.51%
|
-
|
|
Jun 23
2025
|
Gary Dubin |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+50.0%
|
-
|
|
Jun 23
2025
|
Julie L. Gerberding |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+22.51%
|
-
|
|
Jun 23
2025
|
Nanette Cocero |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+50.0%
|
-
|
|
Jun 23
2025
|
Jeryl L Hilleman |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+22.51%
|
-
|
|
Feb 11
2025
|
Shane Maltbie Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,345
-5.16%
|
$4,345
$1.76 P/Share
|
Last 12 Months Summary
Buy / Acquisition
138K
Shares
From
8
Insiders
| Grant, award, or other acquisition | 138K shares |
|---|
Sell / Disposition
17.4M
Shares
From
13
Insiders
| Disposition due to a tender of shares in a change of control transaction | 17.4M shares |
|---|---|
| Open market or private sale | 34.8K shares |